SUNDAY, June 1 (HealthDay News) -- Chemotherapy may be more
effective on melanoma tumors if a protein frequently found in the
growth can first be disabled, a new study reports.
Researchers at the Duke Comprehensive Cancer Center found the
drug ADH-1, which makes it difficult for cells to properly bind to
one another, helped chemotherapy completely destroy the tumors in
twice as many patients than with chemo alone. Sixteen people with
regionally advanced melanoma, in which the cancerous growths appear
and spread mainly on the limbs, participated in the pilot
study.
"Eight of the patients in the study had complete responses to
therapy, meaning their tumors completely disappeared," study lead
investigator Dr. Georgia Beasley, a medical student at Duke, said
in a prepared statement. "This is very encouraging, and we look
forward to continuing this study and then eventually moving on to a
phase III trial."
Without ADH-1, patients generally have complete responses about
25 percent to 35 percent of the time.
"When chemotherapy was applied to the tumor in this weakened
state, it was much more effective compared to conventional therapy
alone," study senior investigator Dr. Douglas Tyler, a surgeon at
Duke and the Durham Veterans Affairs Medical Center, said in a
prepared statement.
The researchers were expected to present their findings Sunday
at the American Society of Clinical Oncology annual meeting, in
Chicago.
"These early results really speak to the importance of
developing combination therapies," Beasley said. "Earlier animal
results showed that using ADH-1 alone was not an effective
treatment, but in combination with chemotherapy, the results, both
pre-clinically and clinically, have been very exciting."
Malignant melanoma is increasing at a rate faster than any other
cancer -- 60,000 new cases are expected to be diagnosed this year
in the United States alone. When the growths spread beyond the
primary site, the disease is rarely curable, and treatment is
limited.
More information
The American Academy of Family Physicians has more about
melanoma.